Published in Bone Miner on February 01, 1994
Altered Calcium and Vitamin D in PMDD or Severe PMS | NCT00005119
Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis. Menopause (2009) 1.04
Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density. Fertil Steril (2008) 0.83
Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab (2014) 0.78
Evaluating the effects of vitamin D and vitamin E supplement on premenstrual syndrome: A randomized, double-blind, controlled trial. Iran J Nurs Midwifery Res (2016) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
Bone densitometry in clinical practice. BMJ (1995) 3.48
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Bone-density measurement. Lancet (1992) 2.38
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res (1995) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum (1991) 1.56
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) (1985) 1.45
Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
The burden of hospitalised fractures in Sweden. Osteoporos Int (2004) 1.41
The use of nasal calcitonin in the treatment of post-traumatic algodystrophy. Br J Rheumatol (1991) 1.40
Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39
Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol (1992) 1.39
Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: the Chingford Study. J Bone Miner Res (1993) 1.38
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int (2009) 1.36
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res (1997) 1.35
Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas (2013) 1.34
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Treatment of osteoporotic fracture. Lancet (1984) 1.33
Cost-equivalence of different osteoporotic fractures. Osteoporos Int (2003) 1.33
Treatment of renal bone disease with 1 alpha-hydroxylated derivatives of vitamin D3. Clinical, biochemical, radiographic and histological responses. Q J Med (1979) 1.32
A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain. Clin Trials Metaanal (1994) 1.32
An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int (2009) 1.31
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone (1994) 1.31
A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol (1998) 1.30
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Does informed consent influence therapeutic outcome? A clinical trial of the hypnotic activity of placebo in patients admitted to hospital. Br Med J (Clin Res Ed) (1986) 1.27
Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM (1995) 1.25
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25
What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis? Ann Rheum Dis (2013) 1.25
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int (2010) 1.24
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21
Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int (2001) 1.20
Diphosphonates and phosphate homoeostasis in man. Clin Sci (Lond) (1988) 1.20
Features of algodystrophy after Colles' fracture. J Bone Joint Surg Br (1990) 1.19
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol (2001) 1.19
Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int (2002) 1.19
Bone fragility in men--where are we? Osteoporos Int (2006) 1.19
Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int (2010) 1.18
Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol (1985) 1.16
Quality of life and vertebral osteoporosis. Osteoporos Int (1992) 1.15
Lifetime risk of hip fractures is underestimated. Osteoporos Int (1998) 1.15
The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int (2011) 1.14
Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) (1984) 1.14
Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 1.13
Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone (1987) 1.12
BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int (2009) 1.12
Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop Relat Res (1987) 1.10
Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporos Int (2004) 1.10
Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int (2010) 1.09
Tools in the assessment of sarcopenia. Calcif Tissue Int (2013) 1.09
Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int (2011) 1.08
The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture. Osteoporos Int (2013) 1.08
Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int (2001) 1.08
A simple clinical score for estimating the long-term risk of fracture in post-menopausal women. QJM (2006) 1.08
Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) (1984) 1.07
Should we use fluoride to treat osteoporosis? A review. Q J Med (1984) 1.07